fbpx

REN Voice and REN Gel Now Available in the US Exclusively from InHealth Technologies

InHealth Technologies has announced that it is now the exclusive
distributor of RENÚ Voice and RENÚ Gel in the United States.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180619005032/en/

RENÚ Voice and RENÚ Gel offer cost-effective short- or long-term
treatment options for vocal fold insufficiency (VFI).1

RENÚ Voice and RENÚ Gel have been proven substantially equivalent to
other available injectable options. Both products are FDA-cleared for
injectable vocal fold augmentation applications.

Both RENÚ Voice and RENÚ Gel provide a greater volume of material than
competitive products: 1.5 cc vs. 1.0 cc.1 The greater volume
ensures enough material in a single syringe to meet patient-specific
treatment requirements. This also helps eliminate the waste,
inconvenience, and added cost of opening additional sterile, preloaded
syringes.

RENÚ Voice is for long-term augmentation. It is a buffered hydrogel of
synthetic, proven-biocompatible calcium hydroxylapatite (CaHA) particles
25 to 45 microns in size for consistent and easy injection.1

RENÚ Gel is for short-term augmentation. It is a buffered hydrogel of
sodium carboxymethylcellulose2 and glycerin. It resorbs
slowly in vivo, providing a scaffold for local tissue
infiltration.3

RENÚ Voice and RENÚ Gel are provided in sterile,
ready-to-use 1.5 cc syringes with ergonomic finger grips and a two-year
shelf life. Physicians can inject the products percutaneously with a
needle of their choice or with the RENÚ Double-Bevel, Transoral Needle,
supplied separately.3,4

RENÚ Voice and RENÚ Gel are backed with comprehensive support from
InHealth Technologies, a global leader that “speaks ENT.”

Constantine Davlantes, Vice President and General Manager of InHealth
Technologies, says, “We are very proud to be distributing RENÚ Voice and
RENÚ Gel. Now, healthcare professionals and patients have a value-driven
option to effectively and cost-effectively treat VFI from a partner
dedicated to the ENT community.”

RENÚ Voice and RENÚ Gel are manufactured by Cytophil, Inc.

For more information or to order RENÚ Voice and RENÚ Gel, call InHealth
Technologies at 800-477-5969, +1-805-684-9337, or visit www.inhealth.com/renu.

Important Safety Information

RENÚ® Voice is indicated for vocal fold medialization and
vocal fold insufficiency that may be improved by injection of a soft
tissue-bulking agent. RENÚ® Voice injection augments the size
of the displaced or deformed vocal fold so that it may meet the opposing
vocal fold at the midline for improved phonation. Vocal fold
insufficiency associated with serious aspiration difficulty may be an
urgent indication.

RENÚ® Gel is indicated for vocal fold medialization and vocal
fold insufficiency that may be improved by injection of a soft
tissue-bulking agent. RENÚ® Gel injection augments the size
of the displaced or deformed vocal fold so that it may meet the opposing
vocal fold at the midline for improved phonation. Vocal fold
insufficiency associated with serious aspiration difficulty may be an
urgent indication.

After injection of RENÚ® Voice or RENÚ® Gel,
patients may experience transient throat soreness, bruising, swelling,
or other local side effects. More rare side effects may include
over-injection or under-injection that may require repeated
intervention. As with any injection, there may be a risk of infection.

About InHealth Technologies

InHealth Technologies, part of Freudenberg Medical LLC, is a world
leader in the field of tracheoesophageal voice restoration after total
laryngectomy, with such well-known brands as Blom-Singer®
Voice Restoration Systems. In addition, InHealth is committed to the ENT
community with products such as RENÚ Voice and RENÚ Gel for the
treatment of vocal fold insufficiency, Katz Extractor®
Oto-Rhino Foreign Body Removers, and the Blom-Singer® Nasal
Septal Perforation Prosthesis.

References

View source version on businesswire.com: https://www.businesswire.com/news/home/20180619005032/en/